
|Videos|August 15, 2014
Improving the Cure Rate and the Burden of Cure in Prostate Cancer
Author(s)Lawrence H. Einhorn, MD
Lawrence H. Einhorn, MD, distinguished professor of medicine, division of hematology/oncology, Indiana University School of Medicine, Giant of Cancer Care: Genitourinary Cancer, discusses new methods being explored to help improve the cure rate in prostate cancer.
Advertisement
Lawrence H. Einhorn, MD, distinguished professor of medicine, division of hematology/oncology, Indiana University School of Medicine, Giant of Cancer Care: Genitourinary Cancer, discusses new methods being explored to help improve the cure rate in prostate cancer.
Clinical Pearls:
- In the past, researchers have been able to successfully demonstrate that drug resistance can be overcome by giving five times the dosage of cytolytic agents.
- Trials are also being developed to look at novel agents and novel combinations in an attempt to improve the cure rate of prostate cancer.
- While a high percentage of patients are cured who are in their early 20s and 30s, late complications are being observed 5-30 years later. These include cardiovascular disease, second malignancies, and peripheral neuropathy.
- Researchers are looking into genetic susceptibilities that make people more at risk for getting late and durable toxicities and to see if anything can be done about it.
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Gedatolisib Improves PFS in HR+/HER2-/PIK3CA-WT Advanced Breast Cancer
2
Nadunolimab Misses Efficacy Mark in TNBC, Despite Strong OS
3
FDA Approves Niraparib/Abiraterone Combo for BRCA2-Mutated mCSPC
4
Giredestrant/Everolimus Improves PFS Across Subgroups After CDK4/6i in ER+/HER2– Breast Cancer
5









































